TY - JOUR
T1 - Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
T2 - The first twenty years
AU - Fillenbaum, Gerda G.
AU - van Belle, Gerald
AU - Morris, John C.
AU - Mohs, Richard C.
AU - Mirra, Suzanne S.
AU - Davis, Patricia C.
AU - Tariot, Pierre N.
AU - Silverman, Jeremy M.
AU - Clark, Christopher M.
AU - Welsh-Bohmer, Kathleen A.
AU - Heyman, Albert
N1 - Funding Information:
The Consortium to Establish a Registry for Alzheimer’s Disease was supported by NIA grant AG06790. This article was supported by NIA grant #1P30 AG028716-01 Claude D. Pepper OAIC (Duke University) (G.G.F.); NIA AG10124 (University of Pennsylvania ADC) (C.M.C.); AG05128 and AG028377 (Bryan ADC, Duke University), and AG11380 (Cache County Memory Study, Duke University) (K.A.W.-B.).
PY - 2008/3
Y1 - 2008/3
N2 - The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) was funded by the National Institute on Aging in 1986 to develop standardized, validated measures for the assessment of Alzheimer's disease (AD). The present report describes the measures that CERAD developed during its first decade and their continued use in their original and translated forms. These measures include clinical, neuropsychological, neuropathologic, and behavioral assessments of AD and also assessment of family history and parkinsonism in AD. An approach to evaluating neuroimages did not meet the standards desired. Further evaluations that could not be completed because of lack of funding (but where some materials are available) include evaluation of very severe AD and of service use and need by patient and caregiver. The information that was developed in the U.S. and abroad permits standardized assessment of AD in clinical practice, facilitates epidemiologic studies, and provides information valuable for individual and public health planning. CERAD materials and data remain available for those wishing to use them.
AB - The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) was funded by the National Institute on Aging in 1986 to develop standardized, validated measures for the assessment of Alzheimer's disease (AD). The present report describes the measures that CERAD developed during its first decade and their continued use in their original and translated forms. These measures include clinical, neuropsychological, neuropathologic, and behavioral assessments of AD and also assessment of family history and parkinsonism in AD. An approach to evaluating neuroimages did not meet the standards desired. Further evaluations that could not be completed because of lack of funding (but where some materials are available) include evaluation of very severe AD and of service use and need by patient and caregiver. The information that was developed in the U.S. and abroad permits standardized assessment of AD in clinical practice, facilitates epidemiologic studies, and provides information valuable for individual and public health planning. CERAD materials and data remain available for those wishing to use them.
KW - Alzheimer's disease
KW - CERAD
KW - Clinical assessment
KW - Consortium to Establish a Registry for Alzheimer's Disease
KW - Incidence
KW - Neuropathological assessment
KW - Neuropsychological assessment
KW - Norms
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=40649085808&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2007.08.005
DO - 10.1016/j.jalz.2007.08.005
M3 - Review article
C2 - 18631955
AN - SCOPUS:40649085808
SN - 1552-5260
VL - 4
SP - 96
EP - 109
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 2
ER -